$GCTK
GlucoTrack Inc

2023 Q3 Form 10-Q Financial Statement

#000149315223028576 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $531.0K $552.0K $654.0K
YoY Change 7.27% -15.6% 18.48%
% of Gross Profit
Research & Development $1.693M $627.0K $469.0K
YoY Change 290.09% 33.69% 46.11%
% of Gross Profit
Depreciation & Amortization $11.00K $3.000K $5.000K
YoY Change 120.0% -40.0% -50.0%
% of Gross Profit
Operating Expenses $2.224M $1.179M $1.123M
YoY Change 139.4% 4.99% 28.64%
Operating Profit -$2.224M -$1.179M -$1.123M
YoY Change 139.4% 4.99% 28.64%
Interest Expense $1.000K $3.000K -$4.000K
YoY Change -50.0% -175.0% -120.0%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$2.223M -$1.176M -$1.127M
YoY Change 139.55% 4.35% 32.12%
Income Tax
% Of Pretax Income
Net Earnings -$2.223M -$1.176M -$1.127M
YoY Change 139.55% 4.35% 32.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10 -$0.09 -$0.07
Diluted Earnings Per Share -$0.10 -$0.09 -$0.07
COMMON SHARES
Basic Shares Outstanding 20.89M shares 20.89M shares 15.47M shares
Diluted Shares Outstanding 22.97M shares 21.56M shares 15.47M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.888M $8.774M $3.854M
YoY Change 112.53% 127.66% -51.17%
Cash & Equivalents $6.888M $8.774M $3.854M
Short-Term Investments
Other Short-Term Assets $281.0K $171.0K $370.0K
YoY Change 50.27% -53.78% 436.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.169M $8.945M $4.224M
YoY Change 109.13% 111.77% -49.18%
LONG-TERM ASSETS
Property, Plant & Equipment $17.00K $27.00K $49.00K
YoY Change -61.36% -44.9% -77.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.000K $10.00K $44.00K
YoY Change -76.92% -77.27% -43.59%
Total Long-Term Assets $26.00K $37.00K $93.00K
YoY Change -68.67% -60.22% -68.47%
TOTAL ASSETS
Total Short-Term Assets $7.169M $8.945M $4.224M
Total Long-Term Assets $26.00K $37.00K $93.00K
Total Assets $7.195M $8.982M $4.317M
YoY Change 104.93% 108.06% -49.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.249M $832.0K $617.0K
YoY Change 75.18% 34.85% -15.48%
Accrued Expenses $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.454M $1.050M $935.0K
YoY Change 50.67% 12.3% -13.82%
LONG-TERM LIABILITIES
Long-Term Debt $184.0K $189.0K $192.0K
YoY Change -3.66% -1.56% -2.54%
Other Long-Term Liabilities $184.0K $189.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $184.0K $189.0K $192.0K
YoY Change -3.66% -1.56% -18.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.454M $1.050M $935.0K
Total Long-Term Liabilities $184.0K $189.0K $192.0K
Total Liabilities $1.638M $1.239M $1.127M
YoY Change 41.7% 9.94% -14.69%
SHAREHOLDERS EQUITY
Retained Earnings -$107.4M -$105.2M -$99.69M
YoY Change 6.79% 5.55%
Common Stock $113.0M $112.9M $102.8M
YoY Change 9.76% 9.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.557M $7.743M $3.190M
YoY Change
Total Liabilities & Shareholders Equity $7.195M $8.982M $4.317M
YoY Change 104.93% 108.06% -49.84%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$2.223M -$1.176M -$1.127M
YoY Change 139.55% 4.35% 32.12%
Depreciation, Depletion And Amortization $11.00K $3.000K $5.000K
YoY Change 120.0% -40.0% -50.0%
Cash From Operating Activities -$1.877M -$954.0K -$916.0K
YoY Change 208.72% 4.15% -5.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$4.000K
YoY Change -100.0% 300.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 -$4.000K
YoY Change -100.0% -233.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 8.730M
YoY Change
NET CHANGE
Cash From Operating Activities -1.877M -954.0K -916.0K
Cash From Investing Activities 0.000 0.000 -4.000K
Cash From Financing Activities 0.000 8.730M
Net Change In Cash -1.877M 7.776M -920.0K
YoY Change 208.72% -945.22% -4.76%
FREE CASH FLOW
Cash From Operating Activities -$1.877M -$954.0K -$916.0K
Capital Expenditures $0.00 $0.00 -$4.000K
Free Cash Flow -$1.877M -$954.0K -$912.0K
YoY Change 208.72% 4.61% -5.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001506983
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
usd
GCTK Adjustments To Additional Paid In Capital Deemed Dividend Resulted From Trigger Of Down Round Protection Feature Of Certain Warrants Granted
AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
usd
CY2023Q2 GCTK Adjustments To Additional Paid In Capital Deemed Dividend Resulted From Trigger Of Down Round Protection Feature Of Certain Warrants Granted
AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted
usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41141
dei Entity Registrant Name
EntityRegistrantName
GLUCOTRACK, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0668934
dei Entity Address Address Line1
EntityAddressAddressLine1
301 Route 17 North
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 800
dei Entity Address City Or Town
EntityAddressCityOrTown
Rutherford
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07070
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
842-7715
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GCTK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20892193 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8774000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2312000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
171000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
8945000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2379000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
40000 usd
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
19000 usd
CY2023Q2 us-gaap Assets
Assets
8982000 usd
CY2022Q4 us-gaap Assets
Assets
2438000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
832000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
672000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
218000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
341000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1050000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1013000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
189000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
195000 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
189000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
195000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1239000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1208000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20892193 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20892193 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15500730 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15500730 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20892193 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20892193 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15500730 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15500730 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
20000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112918000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
103095000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000 usd
CY2022Q4 GCTK Receipts On Account Of Shares
ReceiptsOnAccountOfShares
4000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105218000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101901000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7743000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8982000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2438000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1269000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
929000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
627000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
469000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1194000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1287000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
552000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
654000 usd
us-gaap Operating Expenses
OperatingExpenses
2463000 usd
us-gaap Operating Expenses
OperatingExpenses
2216000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1179000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1123000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2463000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2216000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1179000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1123000 usd
GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
1000 usd
GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
-4000 usd
CY2023Q2 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
3000 usd
CY2022Q2 GCTK Financing Income Expense Net
FinancingIncomeExpenseNet
-4000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2462000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2220000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1176000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1127000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
37000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
30000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2451000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2183000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1170000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1097000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18532553 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18532553 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15465692 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15465692 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21561473 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21561473 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15473813 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15473813 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1230000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2462000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11000 usd
GCTK Stock Issued During Period Value Issuance Of Ordinary Shares Upon Completion Of Public Offering Net Of Offering Expenses
StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponCompletionOfPublicOfferingNetOfOfferingExpenses
8730000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
5000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
229000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7743000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1176000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2023Q2 GCTK Stock Issued During Period Value Issuance Of Ordinary Shares Upon Completion Of Public Offering Net Of Offering Expenses
StockIssuedDuringPeriodValueIssuanceOfOrdinarySharesUponCompletionOfPublicOfferingNetOfOfferingExpenses
8730000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
172000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7743000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5155000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2220000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
20000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
198000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4231000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4231000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1127000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
9000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
47000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3190000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2462000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2220000 usd
us-gaap Depreciation
Depreciation
7000 usd
us-gaap Depreciation
Depreciation
14000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
229000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
198000 usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
5000 usd
GCTK Issuance Of Restricted Shares As Compensation To Board Of Directors
IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors
20000 usd
GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
6000 usd
GCTK Linkage Difference On Principal Of Loans From Stockholders
LinkageDifferenceOnPrincipalOfLoansFromStockholders
6000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
104000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
331000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
173000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
18000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-121000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
114000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2267000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2181000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 usd
GCTK Proceeds Received From Underwritten Public Offering
ProceedsReceivedFromUnderwrittenPublicOffering
8730000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8730000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-10000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-30000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6453000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2215000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2331000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6113000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8784000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3898000 usd
GCTK Deemed Dividend Upon Trigger Of Down Round Protection
DeemedDividendUponTriggerOfDownRoundProtection
855000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105218000 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
8730000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2462000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2220000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1176000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1127000 usd
GCTK Deemed Dividend Related To Trigger Of Down Round Protection Feature
DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
855000 usd
CY2023Q2 GCTK Deemed Dividend Related To Trigger Of Down Round Protection Feature
DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature
855000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3317000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
3317000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2220000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2220000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2031000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2031000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1127000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1127000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15465692 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15465692 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15473813 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15473813 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q2 us-gaap Common Stock Call Or Exercise Features
CommonStockCallOrExerciseFeatures
the Company received gross proceeds of approximately $10,000 thousand for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1270000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.36
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
855000 usd
CY2023Q2 us-gaap Share Price
SharePrice
1
CY2023Q2 us-gaap Share Price
SharePrice
1

Files In Submission

Name View Source Status
0001493152-23-028576-index-headers.html Edgar Link pending
0001493152-23-028576-index.html Edgar Link pending
0001493152-23-028576.txt Edgar Link pending
0001493152-23-028576-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
gctk-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gctk-20230630_cal.xml Edgar Link unprocessable
gctk-20230630_def.xml Edgar Link unprocessable
gctk-20230630_lab.xml Edgar Link unprocessable
gctk-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed